Skip to main content
main-content
Top

14-06-2021 | Osteoarthritis | News

News in brief

Osteoarthritis linked to elevated risk for Parkinson’s disease

Author: Claire Barnard

share
SHARE
print
PRINT
insite
SEARCH

medwireNews: People with osteoarthritis (OA) have a significantly higher long-term risk for developing Parkinson’s disease (PD) than those without, researchers report.

The study, based on data from Taiwan’s National Health Insurance database in 2002–2005, included 33,360 patients with OA and the same number of age- and sex-matched controls without OA.

In all, 0.77% of patients in the OA group developed PD during an average follow-up of 7.74 years, compared with 0.61% of the control group during an average follow-up of 8.67 years, translating into incidence rates per 1000 person–years of 0.99 and 0.71, respectively, and a hazard ratio (HR) of 1.41 after adjustment for potentially confounding factors.

Shin-Liang Pan (National Taiwan University Hospital, Taipei) and co-investigators note that patients with knee or hip OA “appeared to have a higher magnitude of PD risk” relative to controls (adjusted HR=1.55) than patients with non-knee and non-hip OA or those with uncategorized OA (adjusted HRs=1.42 and 1.32, respectively).

“[O]ur findings suggest that clinicians need to be more vigilant about the risk of PD among their OA patients,” write Pan et al in Arthritis Care & Research.

They hypothesize that the association “may be mediated through cytokine-elicited neuroinflammation,” and highlight the need for “[f]urther studies […] to explore the underlying mechanism(s).”

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

Arthritis Care Res 2021; doi:10.1002/acr.24708

share
SHARE
print
PRINT

New additions to the Adis Journal Club

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?